Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Oakridge Global Energy Solutions, Inc. (OGES) Highlighted on Nationwide Financial Services Reporting Program

Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) is leveraging a portfolio of intellectual property, a history of innovation and a system-level view of the current market landscape to deliver the next generation of energy storage solutions. The company’s strategy is to simultaneously deliver groundbreaking technologies while building an industrial-scale platform that includes multiple lithium battery chemistries and form factors optimized to address a collection of key markets – including stationary energy storage, as well as mobile, government, consumer and specialty applications.

In August, Oakridge’s proven strategy took center stage as the company announced that it was to be featured on “New to the Street”, a news program highlighting some of the most promising publically-traded businesses. The show, which is produced by FMW Media Works Corp., airs as paid-programming on select nationwide stations – including The History Channel and A&E – and reaches more than 95 million homes. By securing a spot on “New to the Street”, Oakridge gained national exposure and an opportunity to build upon its brand recognition and increase its market share.

Oakridge’s efforts to expand its market share also include operation in a collection of viable markets. In the United States, the company owns and operates two manufacturing facilities producing its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. On the international stage, Oakridge operates through wholly-owned subsidiary Oakridge Global Energy Solutions Limited, Hong Kong while maintaining a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium ion batteries. Through these operations, Oakridge, under the guidance of its leadership team, is working to establish a sizable footprint in both the domestic and global energy storage markets.

The company is led by a seasoned management team featuring over a century of combined industry experience. Steve Barber, chief executive officer of Oakridge, has over 30 years of experience in the international business sector with dual qualifications in science and law. His unique entrepreneurial approach and strength in building long-term strategic alliances will play a pivotal role in the company’s ongoing efforts to promote sustainable financial growth for the foreseeable future.

For more information, visit

Posted in Oakridge Global Energy Solutions Inc. OGES | Leave a comment

Limoneira Company (LMNR) Building Shareholder Value with Diversified Portfolio of Agribusiness and Real Estate Development Assets

Limoneira Company (NASDAQ: LMNR) is one of the world’s premier integrated agribusinesses. Founded in Ventura County, California, in 1893, the company’s dedication to innovation in the agricultural industry has helped it grow into a leading producer of lemons, avocados, oranges, specialty citrus and other crops that are enjoyed around the planet. Limoneira currently maintains just under 11,000 acres of agricultural production – including 3,010 acres of lemons, 1,169 acres of avocados and 1,654 acres of oranges in California and Arizona. In September, the company announced plans to increase its production capacity through the purchase of more than 750 acres of orchards in California’s San Joaquin Valley.

According to a report by IBISWorld, the domestic orange and citrus groves market is expected to experience steady growth in the years to come. In particular, the report highlights government-sponsored programs as a driver of increased fruit and vegetable consumption. Because of the capital investment requirements and significant lead times for commercial harvesting, the company’s established presence in the agricultural market places it into a strong strategic position to benefit from this increased demand.

In addition to its agricultural investments, Limoneira has a long history of community building through its real estate and community development division. From sustainable, ‘live-walk-work’ communities to commercial rental units, this division provides diversification to the company’s agricultural operations. Last month, Limoneira announced a joint venture with The Lewis Group of Companies, a leading residential real estate investment firm, for the planned development of roughly 1,500 residential units comprising a 500-acre community in Santa Paula, California. Limoneira expects to receive approximately $100 million of net cash flow from the Santa Paula Gateway project over its 10-year duration.

“The Gateway Project is a great example of Limoneira unlocking the value of its extensive real estate assets,” Harold Edwards, president and chief executive officer of Limoneira, stated in a news release. “We believe that over time, this project this will result in significant cash flows, which will allow us to significantly increase the operating results of our global agribusiness. We are confident this will enhance the long-term value of our company for our shareholders and deliver on our stated goal of becoming one of the leading citrus agribusinesses in the world.”

In April, Limoniera’s innovative approach to the agribusiness sector was recognized by Grocery Headquarters with the ‘Grocery Headquarters Annual Produce Trailblazer Award’. Receiving this award underscored the company’s commitment to best-in-class practices while serving as a testament to the dedication of its employees. Through its recent efforts to build on this success in both its agribusiness and real estate segments, Limoneira is strategically positioned to promote sustainable growth and maximized shareholder value for the foreseeable future.

For more information, visit

Posted in Small Cap News | Leave a comment

Bollente Companies, Inc. (BOLC) Challenging Industry Giants with Disruptive trutankless® Products

Bollente Companies is growing a diverse portfolio of companies with an interest in disruptive technologies that positively impact the environment, consumer lifestyles and emerging economies. The company’s flagship brand, trutankless®, manufactures and distributes tankless water heaters that leverage proprietary technology in order to outperform and outlast both their tank and tankless predecessors – including those produced by industry giants such as AO Smith (NYSE: AOS) and General Electric (NYSE: GE) – in terms of energy efficiency, output and durability.

trutankless achieves this industry-leading performance by integrating its products with existing home automation systems through an intuitive online control panel, allowing homeowners to easily control water temperature to within one degree and monitor usage directly from their computer or mobile devices. These groundbreaking features helped trutankless claim the ‘Best Home Technology Product’ award at the 2014 NAHB International Builders Show and the ‘Governor’s Award of Merit for Energy and Technology Innovation’ at Arizona Forward’s Environmental Excellence Awards.

By targeting the home automation market, Bollente is in a strong position to capitalize on rapid industry growth. According to a report by ABI Research, the U.S. home automation market will exceed $5.5 billion in 2016, and more than 500 million wireless smart home monitoring devices will be installed worldwide by 2018. This market performance, in addition to new Department of Energy guidelines for water heater efficiency, should provide a solid platform upon which to promote sustainable financial growth in the months to come.

“The new Department of Energy guidelines for water heaters are going to impact the majority of homes that currently use traditional tank water heaters,” Michael Stebbins, president of trutankless, stated in a news release. “Tanks will become larger and costlier to install, and homes requiring tank heaters that hold 55 or more gallons will have to upgrade to a heat pump for twice the cost, or go tankless. We are pleased to offer whole-home electric tankless solutions that already exceed the new Energy Factor guidelines.”

In the first three quarters of 2015, Bollente has made considerable progress toward improving its position in the home automation market through the introduction of two innovative products. In January, the company introduced truCirc, a state-of-the-art smart-home water circulation pump that limits energy consumption by tracking water usage and predicting hot water demand. In April, Bollente announced the release of Vero™, a new line of electric tankless water heaters geared toward budget-driven customers. These inventive products are expected to play a key role in the company’s ongoing efforts to increase its market share.

Moving forward, Bollente will look to capitalize on the established industry position of its trutankless brand while continuing to evaluate additional acquisition opportunities that can achieve strong profitability and generate lasting returns for its shareholders.

For more information, visit

Posted in Small Cap News | Leave a comment

OurPet’s Company (OPCO) Reroutes Communication Plan to Maximize Outreach, Better Utilize Funds

OurPet’s Company designs, produces and markets a broad line of innovative pet products and accessories under the OurPets and Pet Zone brands, sold in leading pet specialty retailers, food, drug and mass merchandisers, direct-mail catalog and Internet retailers. The company’s extensive product line is built on its intellectual property portfolio of more than 160 patents in either issued or pending status.

Coinciding with corporate growth among its target markets, OurPet’s yesterday announced a new strategy to more efficiently utilize corporate resources. Moving forward, OurPet’s says it will no longer conduct quarterly earnings teleconferences, and instead is ramping up its online communications and social media strategies to ensure that shareholders have ongoing access to the company’s most recent news, financial reports and progress.

“We have hosted consistent quarterly earnings calls for the 18 months, and have not seen participation meet our targets. In light of this, we feel that we can allocate our funds toward more worthy causes, and have identified more far-reaching and cost-effect routes to disseminate company news and financial reports,” OurPet’s CFO Scott Mendes stated in the news release. “This decision further emphasizes our commitment to increasing shareholder value, transparency and communication. We look forward to providing our shareholders and potential investors with more readily available, up-to-date corporate information.”

As part of its new communications strategy, OurPet’s recently engaged DreamTeamNetwork to boost its social media, presence, disseminate news releases, achieve targeted marketing and establish a mobile version of the OurPet’s website.

For more information visit and

Posted in OurPet’s Company OPCO | Leave a comment

International Stem Cell Corp. (ISCO) Continues Stem Cell Based Research and Development to Promote Rejuvenation of Dying Cells

The International Stem Cell Corporation, a biotechnology company, continues its developmental research of using stem cells to advance regenerative medicine. The company uses stem cell technology called parthenogenesis that uses unfertilized eggs to address immune system rejection. These eggs have duplicate sets of human leukocyte antigen genes (HLA) that lessen the chance of immune rejection. A single line of these cells can treat millions of people. Furthermore, ISCO can draw hpNSC (human parthenogenetic neural stem cells) from the unfertilized eggs for self-renewing processes related to degeneration.

For example, after continuous successful testing, ISCO believes that their hpNSC can replace dead and dying neurons while also protecting existing ones when transplanted into the brain of someone with Parkinson’s disease. Likewise, ISCO scientists have taken steps to develop human retinal epithelium (RPE) cells that can treat many eye diseases like age-related macular degeneration. Along with that research, the company is among the first in the world to develop a method (CytoCor) for creating corneal tissue and cells to treat blindness.

ISCO recently announced its development of technology that creates functional cartilage from a person’s skin to treat osteoarthritis, a joint disease that erodes cartilage. The company is also pursuing other therapeutic systems that “can potentially be treated with the patient’s own cells,” said its chief scientific officer, Ruslan Semechkin, PhD.

While continuing to develop new regenerative techniques, ISCO also maintains a cosmeceutical line called Lifeline Skin Care Inc. This business manufactures cosmetic skin care products around the world. It uses parthenogenetic stem cells along with vitamins and minerals to create a rejuvenating serum that promotes healthy skin.

For more information about ISCO, visit

Posted in International Stem Cell Corp. ISCO | Leave a comment

Multi-Dimensional Approach Cements Latitude 360, Inc. (LATX) in Entertainment, Upscale Casual Dining and Fantasy Sports Market

From entertainment and food to overall guest experience, Latitude 360 is all about a multi-dimensional approach that increases corporate and shareholder value. Latitude 360 is an award-winning pioneer of a dining and entertainment venues that blend premier upscale casual dining with a variety of entertainment choices such as luxury bowling, dine-in movies, high definition sports and more.

In addition to the key offerings mentioned above, each 360 location include Las Vegas-style live performance showroom, a feature bar hosting the area’s top musicians and/or DJs, game arcade, and luxury cigar lounge, and many choices of private meeting space. Through agreements with Monster Beverages (NASDAQ:MSNT) and Pepsico (NYSE:PEP), and paired with an impressive menu ( from its Latitude 360 Grille, Latitude 360 is committed to creating a branded “360 Experience” that encourages customer loyalty and word of mouth marketing.

The company also recently added dimension to its payment options via partnership with MyCheck, a mobile payment technology platform. The Latitude 360 mobile app, scheduled for launch in October, will allow guests to easily order beverage and dessert items off the menu, reorder other items already on their check, and then easily view, split their bill with friends, and pay using multiple linked payment methods such as Apple Pay (NASDAQ:AAPL). Guests will also be able to view their status and redeem benefits from their Latitude 360 Membership and Rewards program — all from the Latitude 360 app their smartphone.

Launched in 2014, Latitude 360’s monthly club membership program provides guests with a cache of monthly entertainment assets at a value price, as well as exclusive access to a 360 Club Concierge service – all for a monthly fee. The program has quickly grown to more than 5,000 monthly paying members.

Latitude 360 also recently expanded its entertainment offerings with the recent partnership and pending acquisition of Major League Fantasy (MLF), a leader in the daily fantasy sports industry, and concurrently launched its own branded daily fantasy sports service: “360 Fantasy Live” ( By adding yet another dimension to its existing locations, “360 Fantasy Live” enables Latitude 360 to drop anchor in the rapidly growing fantasy sports market, which is expected to reach $6 billion-$10 billion by year-end 2016. With this offering, Latitude 360 is now one of the first live, multimedia venues to offer in-house, high-stakes, competitive daily fantasy events.

How do you house such a multi-dimensional operation under one roof? Lots and lots of space. Latitude 360’s current venues range from 35,000-85,000 square feet packed full of eating and entertainment options that appeal to a broad base of guests, private events and corporate clients.

You’ll find a Latitude 360 location in Jacksonville, Florida, Pittsburgh, Pennsylvania, and Indianapolis, Indiana, each of which is highly focused on providing a branded “360 EXPERIENCE.” Latitude 360 also currently operates two additional locations under management agreements in Syracuse, New York, and Saucon Valley, Pennsylvania, under the Revolutions brand – These locations will be rebranded as Latitude 360 venues in the fourth quarter of this year.

Topping off its multi-dimensional approach to brick and mortar expansion, increased corporate and shareholder value, and growing entertainment options, is a visionary management team with a diverse line of experience. Under this leadership, Latitude 360 anticipates opening additional 360 venues in major cities overseas and domestically.

For more information visit

Posted in Latitude 360 | Leave a comment

OurPet’s Company (OPCO) Engages DreamTeamNetwork Investor Relations Services

OurPet’s Company, a leading proprietary pet supply company, announces that it has engaged the corporate communication and investor relation services of DreamTeamNetwork (“DTN”). Based in Austin, Texas, DTN has assisted more than 300 public companies with their efforts to implement strategic investor relations, and digital and social media communications campaigns.

“OurPet’s Company continues to gain visibility among the public and investment communities, and we want to supplement our efforts with a social-media focused powerful communication strategy,” stated Scott Mendes, CFO of OurPet’s Company. “We’re excited to partner with DreamTeamNetwork to deliver on this mission and help us attain a larger and more effective information distribution strategy that accurately relays our progress and upcoming initiatives to existing and potential shareholders.”

Using a precise blend of investor relations and public relations, DTN will leverage its family of unique and far-reaching brands, along with an extensive network of partners, daily and weekly newsletters, social media channels, blog and other outreach tools, to strengthen OurPet’s social media activity and communication.

DTN will also assist OurPet’s in establishing a mobile version of the Company’s website, as well as build an email marketing program to optimize the conversion rate of traffic. Together, these efforts will provide OurPet’s maximal exposure to the investment community via social media, message board platforms and far-reaching key distribution points.

“We’re honored to come alongside OurPet’s to maximize the Company’s online outreach and communication efforts,” stated DTN Managing Director Michael McCarthy. “Our role with this new partnership is to synchronize OurPet’s communication efforts and provide the investment community a thorough look at the Company’s management, operations, initiatives and achievements.”

Let us hear your thoughts below:

Posted in OurPet’s Company OPCO | Leave a comment

Catalyst Pharmaceuticals, Inc. (CPRX) is “One to Watch”

Targeting rare, or underserved conditions, where the potential exists for disruptive innovation has long been a successful inside track strategy for the biopharma sector. A person doesn’t have to look any further than the niche market for a drug like Sabril® (vigabatrin), approved for human use by the FDA in 2009, as well as during the late 1980’s in the EU for treating infantile spasms and refractory complex partial seizures. Sanofi’s (NYSE: SNY) Sabril, the North American rights to which have been out-licensed to Lundbeck (OTC: HLUYY), raked in $120 million last year, and saw a 35 percent appreciation in revenues when compared with 2013.

And yet Sabril’s NCE (New Chemical Entity) exclusivity has expired and its orphan drug exclusivity expires in August of next year, opening the door wide to innovators like Catalyst Pharmaceuticals (NASDAQ: CPRX). Catalyst has a vast amount of experience with its own version of vigabatrin (gamma-vinyl-GABA), CPP-109, and is rapidly developing an improved antiepileptic indication known as CPP-115. CPP-115 acts to inhibit GABA-aminotransferase (GABA-AT), much like vigabatrin, but has also shown itself to be some 200 times more potent when tested via both in-vitro and animal model, where its use resulted in much higher levels of the primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). Given that some 30 percent of the 3 million Americans who either experience an unprovoked seizure each year, or who are diagnosed with epilepsy, find themselves wracked with seizures despite the best modern medicines and surgical techniques, a powerful antiepileptic like CPP-115 could be a real godsend.

Catalyst’s decision to strike while the iron is hot and develop a generic version of Sabril, given that that there are no listed patents and the company believes its processes do not infringe on any unexpired patents, is a shrewd move that sets up CPP-115 for more widespread adoption across its potential indication spectrum. Already granted orphan drug designation by the FDA for infantile spasms, as well as orphan medicinal product designation in the EU for a severe form of epilepsy involving infantile spasms known as West Syndrome, CPP-115 is also being developed for other neurological conditions associated with reduced levels of neuronal excitability regulator GABA, such as PTSD, and Tourette’s syndrome (TS). CDC estimates put the number of TS patients each year in the U.S. alone at somewhere north of 138,000 and PTSD, once understood as only a battlefield-induced ailment, is now thought to impair as much as 7.8 percent of all Americans at some point in their lives. What all of this really means is that the upside for an effective broad-spectrum antiepileptic treatment, without the side effects typical of the current standards of care, could be considerable.

In fact, CPRX reported top-line results just this June for an open-label, proof-of-concept trial of CPP-109 in treatment-refractory TS patients, where one quarter of those taking CPP-109 exhibited a clinically significant reduction in tics. The company’s massive, established body of clinical trial vision safety data from previous work with vigabatrin, including a 2007 bioequivalence study of its formulation against the European equivalent of Sabril, places CPRX out in a leadership position here to develop a generic, and should help the company nail the FDA and institutional review board bioequivalence study. CPP-115 may address one of the primary concerns with chronic use of vigabatrin, visual field defects, and the significantly enhanced potency also means CPP-115 could be administered using methods and dosages that could potentially make a world of difference for patients. Moreover, the development of CPP-115, for which the less-potent, riskier vigabatrin analog CPP-109 is currently acting as a kind of temporary research surrogate (to demonstrate the efficacy of GABA-AT blockade), aligns nicely with CPRX’s overall vision of developing novel treatments for a variety of rare neurological and neuromuscular conditions.

After all, Catalyst’s main focus is on its flagship candidate, a neuronal potassium channel blocker known as Firdapse®, for which the company recently initiated a rolling NDA submission to the FDA. Firdapse has already been granted orphan drug designation and breakthrough therapy designation for treating the rare muscle weakening autoimmune disorder commonly associated with SCLC (small-cell lung cancer), known as LEMS (Lambert-Eaton myasthenic syndrome), as well as a group of muscle weakness conditions known as CMS (congenital myasthenic syndromes), and the most common form of central vestibular nystagmus (involuntary eye movement), downbeat nystagmus. Firdapse has been marketed in the EU since 2010 for LEMS and has been put forth by the European Academy of Neurology as well, as a frontline symptomatic treatment for this potentially severely disabling disease.

Originally in-licensed for North America via a strategic collaboration with BioMarin Pharmaceuticals, which has CPRX spearheading the clinical development, Firdapse’s main target is treating the roughly 3,000 patients each year who are stricken with LEMS, half of whom have cancer – most predominantly SCLC, of which there are around 33,180 cases each year according to the American Cancer Society’s 2015 estimates. Firdapse has shown statistically significant improvements for a whole host of independent neurological functions in LEMS patients across numerous randomized, double-blind, placebo-controlled studies, as well as in one double-blind study with an active comparator. Recently having completed pivotal Phase 3 safety and efficacy clinical trialing via a multicenter, double-blind, placebo-controlled, randomized discontinuation trial that yielded positive top-line results (followed by an open-label extension period), Firdapse has also been made available by CPRX on a compassionate use basis under an Expanded Access Program in the interim preceding FDA approval, where it provides treatment to seriously ill patients for whom no other treatments are available.

Moving forward, CPRX remains squarely focused on the Firdapse NDA, while also pursuing CPP-115 as a candidate for future treatment refractory TS trials, and the company looks to be on track for approval of Firdapse sometime next year. Firdapse represents a distinct alternative to other attempts at managing the symptoms of LEMS, including monthly immunoglobulin IV infusions and medications like amifampridine capsules or corticosteroids, which are only marginally effective.

Substantial experience developing antiepileptic drugs and a rapidly advancing pipeline where its lead candidate is in Phase 3 are great signs of health for CPRX, which could be winding down the capital burn rate-intensive phase typical of development-stage biopharma companies within the very near future as Firdapse commercialization looms large on the horizon. Investors will want to keep a close eye on the company for news about its generic Sabril development and FDA approval of Firdapse.

Or, take a closer look right now by visiting

Posted in Ones to Watch | Leave a comment

Legacy Ventures International, Inc. (LGYV) Acquires RM Fresh Brands

Canadian-based Legacy Ventures International was founded on the idea of seeking out creative companies with game-changing potential, allowing Legacy Ventures to provide the capital, oversight, and connections necessary to bring all the innovation and passion to fruition. To this end, Legacy Ventures has announced the acquisition of all outstanding common stock of RM Fresh Brands, Inc., based in Toronto. Through the Share Exchange Agreement, Legacy Ventures issued two million shares of common stock to the shareholders of RM Fresh in exchange for all the issued and outstanding shares of RM Fresh. As a condition of the agreement, 35,800,000 shares of Legacy Ventures were cancelled, leaving Legacy with 28,180,000 shares of common stock issued and outstanding. Legacy Ventures will file a Current Report with the SEC on Form 8-K within the required period.

RM Fresh Brands services food and beverage retailers and distributors who are looking for innovative, trend-setting products across North America and in international markets. With a focus on sustainable, category changing consumables, RM Fresh Brands represents an extensive portfolio of highly desirable brands, including Boxed Water. The principals of RM Fresh, Ron Patel and Mirwan Ferris, will remain as officers and directors of RM Fresh.

Upon closing of the transaction, Rehan Saeed resigned as the President and CEO of Legacy Ventures, and Evan Clifford was appointed by the Board of Directors as the new President and CEO. Mr. Clifford has extensive experience in entrepreneurial start-ups in both the private and public sector. Over the last fifteen years, Mr. Clifford has built and maintained extensive relationships throughout many different industries, and has earned a platinum record managing some of Canada’s top music artists, while playing a leading role in building one of the world’s foremost electric car companies. He has been a speaker at the world renowned Idea City Conference, and has coached companies and individuals to achieve personal and professional success throughout the last decade.

For further information on Legacy Ventures or RM Fresh Brands, visit or

Posted in Small Cap News | Leave a comment

Stellar Biotechnologies Inc. (SBOTF) and Amaran Biotechnology Inc. Continue Successful Collaboration

Stellar Biotechnologies and Amaran Biotechnology are happy to announce that their continuing alliance has proved successful in their primary objective to meet GMP-grade specifications of Stellar KLH for OBI-822 immunotherapy. KLH (Keyhole Limpet Hemocyanin) is a protein that stimulates the immune system while OBI-822 is the immunotherapy that uses this protein to combat immune disorders, cancer, and inflammatory responses.

The two companies collaborated in 2013 to manufacture OBI-822 so that it uses the Stellar KLH protein. Next, the companies hope to create large scale optimization processes to commercial manufacturing levels for widespread use. Amaran even commissioned a new biological production and research center in Taiwan’s Hsinchu Biomedical Science Park in Hsinchu County, Taiwan in preparation for immunotherapy expansion.

Stellar Biotechnologies is a world leader in KLH production while boasting a manufacturing facility that is the first of its kind. Amaran Biotechnology is a biopharmaceutical manufacturer that designs, develops, and produces pharmaceuticals in Taiwan.

Catherine Brisson, Chief Operating Office for Stellar Biotechnologies Inc., stated that,”Stellar’s collaboration with Amaran is an exciting clinical project. She continued that, “Through close cooperation with the Amaran team, we achieved each primary objective on-time and to the particular specifications required. We look forward to the scale-up stage with Amaran and to providing our partners with GMP Stellar KLH™ for their immunotherapy programs.”

Similarly, Tessie Che, General Manager and Chair of Amaran’s Board of Directors, stated, “We are very pleased with the success of our alliance with Stellar Biotechnologies, and the progress made towards commercial scale production of KLH for OBI-822.All of the programs that support OBI-822 and that will move this important immunotherapy closer to market launch are on track.”

Thanks to their continued collaboration, Stellar and Amaran have met the guidelines and specifications for the OBI-822 production alongside with the development and formulation of the Stellar KLH protein. When the protein is used with the immunotherapy, it can act as an immune stimulant, carrier molecule, or therapeutic vaccine conjugation. The companies anticipate the continued growth of their joint endeavor.

For more information, visit

Posted in Small Cap News | Leave a comment